| Active Not Recruiting | A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection Viral Hepatitis | Phase 2 | 2025-08-05 |
| Recruiting | A Study to Evaluate Tobevibart+Elebsiran in Participants With Chronic HDV Infection Not Virologically Suppress Viral Hepatitis | Phase 3 | 2025-07-30 |
| Recruiting | Safety and Preliminary Efficacy of VIR-5525 and VIR-5525 + Pembrolizumab in Participants With Locally Advanced Solid Tumor Malignancies, EGFR Positive Solid Tumors, EGFR | Phase 1 | 2025-07-22 |
| Active Not Recruiting | A Study to Evaluate Tobevibart + Elebsiran in Chronic HDV Infection Viral Hepatitis | Phase 3 | 2025-03-12 |
| Recruiting | Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer Hormone-refractory Prostate Cancer | Phase 1 | 2023-08-10 |
| Completed | A Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics and Safety of VIR-2218 Renal Impairment | Phase 1 | 2023-06-01 |
| Completed | A Platform Study to Evaluate Investigational Therapies in Chronic Hepatitis B Infection Hepatitis B, Chronic | Phase 1 / Phase 2 | 2023-05-10 |
| Terminated | A Phase 2 Study to Evaluate the Efficacy and Safety of VIR-2482 for the Prevention of Illness Due to Influenza Influenza A | Phase 2 | 2022-10-30 |
| Recruiting | Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Hepatic Impairment, Cirrhosis | Phase 1 | 2022-09-21 |
| Active Not Recruiting | SOLSTICE: Combination Therapy for the Treatment of Chronic Hepatitis D Infection. Hepatitis D, Chronic | Phase 2 | 2022-09-17 |
| Recruiting | To Access the Safety and Effects of Intravenous Administration of VIR-5818 Alone and in Combination With Pembr Locally Advanced or Metastatic HER2-Expressing Cancers | Phase 1 / Phase 2 | 2022-04-13 |
| Terminated | Relative Bioavailability, Safety, and Tolerability of Single-dose Sotrovimab Injection in Adults (COSMIC) Covid19 | Phase 1 | 2022-03-28 |
| Active Not Recruiting | Study of VIR-2218, VIR-3434, and/or PEG-IFNα in Subjects With Chronic Hepatitis B Virus Infection Hepatitis B, Chronic | Phase 2 | 2021-07-11 |
| Completed | A Study to Investigate the PK, Safety, and Tolerability of Sotrovimab vs Placebo Administered IV or IM in Japa Covid19 | Phase 1 | 2021-07-06 |
| Terminated | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. Covid19 | Phase 3 | 2021-06-10 |
| Completed | Safety, Tolerability and Pharmacokinetics of Second Generation VIR-7831 Material in Non-hospitalized Participa Covid19 | Phase 2 | 2021-02-18 |
| Completed | VIR-1111: A Prototype Human CMV-based Vaccine for Human Immunodeficiency Virus (HIV) in Healthy Volunteers HIV I Infection | Phase 1 | 2020-12-28 |
| Completed | VIR-7831 for the Early Treatment of COVID-19 in Outpatients Covid19 | Phase 2 / Phase 3 | 2020-08-27 |
| Completed | Study of VIR-2218 With or Without Pegylated Interferon Alpha-2a for Treatment of Chronic Hepatitis B Virus Inf Chronic Hepatitis B | Phase 2 | 2020-07-03 |
| Completed | Study of VIR-3434 in Healthy Volunteers and Patients With Chronic Hepatitis B Virus Infection Chronic Hepatitis B | Phase 1 | 2020-05-26 |
| Completed | Study of VIR-2482 in Healthy Volunteers Influenza A | Phase 1 | 2019-08-26 |
| Completed | Study of VIR-2218 in Healthy Subjects and Patients With Chronic Hepatitis B Chronic Hepatitis B | Phase 1 / Phase 2 | 2018-11-14 |
| No Longer Available | Sotrovimab Expanded Access Treatment Protocol (COVID-19) Covid19 | — | — |